

Manufacturer's perspective: New Sabin IPV

Meng LI

China National Biotech Group Company Limited

Sep 27, 2017

Contents

1

Use of polio vaccines in China

2

Introduction of CNBG's sIPV



Use of polio vaccines in China



OPV vaccination in China

1960

- tOPV launched in China.
- 2 manufacturers: CNBG-NVSI and IMBCAMS.

1965

- tOPV vaccination take-up on the rise.

1978

- tOPV adopted by the China NIP.
- Administrated at 2, 3, 4 months and 4 years old.

2000

- WHO-WPR polio-free certification


2015

- Global certification of WPV2 eradication
- CNBG-BBIBP's bOPV got licensure in China.

GPEI Polio eradication and endgame strategic plan 2013-2018



国药集团
SINOPHARM



China tOPV-bOPV switchover and immunization strategy

Supplier Landscape

Supplier


- Sanofi Pasteur (2009)
- IMBCAMS (2015)
- CNBG-BBIBP (2017)

R&D pipeline

No.	Manufacturer	Product name	Stage
1	CN BG-WIBP	Sabin IPV (Vero cell)	Phase II/III (2019)
2	Sinovac	Sabin IPV (Vero cell)	Phase II
3	Sinovac	Sabin IPV, absorbed (Vero cell)	IND (under review)
4	Minhai	Sabin IPV (Vero cell)	CTA

Demand and Supply

IPV demand and supply in China, 2016



Source: NIFDC lot release data 2016

2017-9-27

Demand in China

- 18M newborns each year, in accordance with the Plan, 2017-2018/19 requires 18M doses, 2019 onwards requires 72M doses

Supply in China

- CNBG could produce 10M doses IPV by end of 2017, which will fill the unmet need in the domestic market. CNBG can supply 45M-70M doses/year after Wuhan site got the licensure in 2018.
- IMBCAMS is expanding its capacity, the plan is to supply 60M doses/year.
- After launch of other pipeline products and DTaP-IPV combos, China will have excess capacity of IPV to supply other countries.



Introduction of CNBG's sIPV



Advantage of CNBG sIPV

Advanced Technology

- ⑩ Bioreactor technology
- ⑩ Large scale two-step purification
- ⑩ High immunogenicity
- ⑩ Good safety
- ⑩ Good cross-protection

High Quality

- ⑩ Specifications meet the WHO and EU requirements
- ⑩ Full-coverage quality assurance system in place

Capacity

- ⑩ 2 production sites
- ⑩ 45M-70M annual capacity with excess amount for international market after 2020.

Collaboration opportunities

Finished Products

Fill-finish

Co-develop sIPV containing vaccines

Meng Li,

Director of International Cooperation Department (ICD), CNBG

limeng3@sinopharm.com

Jenny Qu, Sr. Manager, ICD, CNBG

quliang@sinopharm.com



谢谢！
THANKS



Meng Li,
Director of International Cooperation Department (ICD), CNBG
limeng3@sinopharm.com

Jenny Qu, Sr. Manager, ICD, CNBG
quliang@sinopharm.com